Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
|Articles|March 19, 2018
Lower Drug Costs Improves Adherence Among Heart Attack Survivors
Author(s)Jenna Payesko
Reducing financial barriers may increase the use of evidence-based treatments and improve adherence to medications.
Advertisement
Research presented by the Duke Clinical Research Institute at the 67th American College of Cardiology's Annual Scientific Session found that heart attack survivors are more likely to comply with drug regimens if vouchers waive co-payments.
The finding is based on a study, known as ARTEMIS, of 11,001 people treated for myocardial infarction (MI) at 300 US hospitals between June 2015-2016. All of the patients studied had health insurance - 64% had private insurance, 42% were covered by Medicare and 9% Medicaid.
"Our study confirms some of our thoughts on how drug prices affect doctors and patients behaviors," lead author Tracy Wang, MD, associate professor of medicine, Duke University School of Medicine, said in a statement.
For more information, please visit
Advertisement
Related to this article
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
5